Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 30, 2017

DAIC’s Website Broke 1 Million Pageviews; Two Key TCT Takeaways

DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys and speak to readers at site visits and conferences, one of the clearest views we have of reader interests is based on what they are reading on our website, e-newsletters and digital editions. We have responded to these analytics in what we publish and how we cover new cardiovascular technology. The result has been a big increase in our online readership over the past year. For the first time, DAIC’s website broke 1 million pageviews in November 2016. We wanted to thank our readers for helping us reach this milestone. 

See a list of the “Most Popular Cardiology Articles of 2016 From DAIC.”

See the list of “Top Cardiology Videos on DAIC in 2016.”

 

Two Key Takeaways at TCT 2016

After decompressing from the interventional information overload at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in November, I felt there were two big technology takeaways requiring an in-depth review.  These included the EXCEL Trial and the results of three studies that compared bioresorbable polymer metallic drug-eluting stents (DES) to the current standard durable polymer metallic DES. 

The EXCEL Trial was the biggest news at TCT.16. It compared the use of the Abbott Xience V DES to coronary artery bypass graft (CABG) surgery in patients with left main disease. The result of this large randomized trial was that both have equal outcomes. You can read the article with more detail at  "Stents Have Equal Outcomes to Bypass Surgery in EXCEL Trial."

Durable drug-carrier polymers on DES have been implicated as the cause of late-stent thrombosis, which has led to long-duration use of dual antiplatelet therapy (DAPT). The introduction of bioresorbable polymers was expected to eliminate late events and the need for long-term DAPT. However, results from three trials of bioresorbable polymer DES showed equal outcomes and no apparent benefit. Read more detail and here Boston Scientific's response to the data in the article "Bioresorbable Polymers on Metallic Stents Show No Superiority to Durable Polymer Stents."

 

New DAIC Editorial Board Members

DAIC recently added two new Editorial Board members who are experts in cutting-edge interventional and structural heart technologies. The first is Azeem Latib, M.D., an interventional cardiologist at Università Vita-Salute San Raffaele Milano, Milan, Italy. He is a regular speaker at  TCT and other conferences. His research interests include new transcatheter heart valve repair and replacement technologies and bioresorbable stents. Read his recent article on the Cardioband annuloplasty device, "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."

Our second new board member is Torsten Vahl, M.D., director of experimental and translational research and assistant professor of medicine at Columbia University Medical Center, The Center for Interventional Vascular Therapy. He also is a regular speaker at TCT and is involved in bleeding-edge research and trials for new structural heart interventions. Watch a video interview with Vahl at TCT 2016, "Transcatheter Valve Technology Advancements at TCT 2016."
 

Related Content

Edwards Recalls Sapien 3 Ultra Delivery System Due to Burst Balloons During Surgery
News | Heart Valve Technology | August 22, 2019
Edwards Lifesciences is recalling the Sapien 3 Ultra delivery system after receiving reports of burst balloons during...
FDA Approves Sapien 3, CoreValve Evolut TAVR Valves for Low-risk Patients

Left, an illustration of the beginning of deployment for a CoreValve Evolut self-expanding transcatheter aortic replacement (TAVR) valve. Right, an illustration of the final balloon expansion of an Edwards Lifesciences Sapien 3 TAVR valve. Both valves received simultaneous FDA clearance for use in low-risk surgical patients. Clearing this last hurdle now allows wide-spread use of minimally invasive TAVR in all patients who otherwise would need an open-heart surgical valve replacement. 

Feature | Heart Valve Technology | August 16, 2019 | Jeff Zagoudis, Associate Editor, and Dave Fornell, Editor
In one coordinated move, the U.S. Food and Drug Administration (FDA) opened transcatheter aortic valve replacement (...
Abbott Receives U.S. Approval of Next-generation MitraClip G4
Technology | Heart Valve Technology | July 17, 2019
Abbott has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip heart valve repair...
Neovasc Tiara, Reducer Transcatheter Devices Featured at CSI Frankfurt 2019 Conference
News | Heart Valve Technology | July 09, 2019
Neovasc Inc. announced that its Tiara transcatheter mitral valve replacement (TMVR) device and its Neovasc Reducer...
Study Shows Inducing a Heart Attack Helps Valve Patients. This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates some of the tissue in the septum to allow for a larger LVOT area.

This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates (kills) some of the tissue in the cardiac septum to allow these valves to fit better and allow for an enlarged neo-LVOT for patients who otherwise could not receive this therapy. 

News | Heart Valve Technology | July 03, 2019
A study of a procedure developed at Henry Ford Health System shows inducing a heart attack in patients with heart...
CMS Finalizes Updates to Coverage Policy for Transcatheter Aortic Valve Replacement
Feature | Heart Valve Technology | June 24, 2019
The Centers for Medicare and Medicaid Services (CMS) recently finalized its decision to update the national coverage...
Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days
News | Heart Valve Technology | June 11, 2019
June 11, 2019 — Abbott recently announced positive late-breaking data from its TRILUMINATE...
DSM and SAT Partnering to Develop Next-Generation, Cost-Effective Heart Valve
News | Heart Valve Technology | June 04, 2019
Royal DSM recently announced a collaboration with Strait Access Technologies (SAT), to develop the world’s first...

The MitraClip is one example of a transcatheter mitral valve repair or replacement (TMVR) device used in the structural heart repair program at Henry Ford Hospital.

Podcast | Heart Valve Technology | May 31, 2019
Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of
Overlay Init